1. ALLA AKTIER
  2. NYHETER
  3. IMMUNOVIA

Immunovia

Nyheter Immunovia Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

INVITATION TO IMMUNOVIA’S Q3 PRESENTATION

LUND, Sweden – Immunovia (publ.), the pancreatic cancer diagnostics company, will publish its third quarter 2025 results on November 26th, 2025, at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report, together with the presentation slides, will be available at www.immunovia.com.

The presentation will be held by CEO Jeff Borcherding, who will share the company’s third-quarter developments. The presentation will be conducted in English and followed by a Q&A session.

You are welcome to join via webcast or phone, see details below. Please dial in a few minutes before the presentation starts.

Telephone numbers and webcast
Sweden: +46 (0) 8 5051 0031

United Kingdom: +44 (0) 207 107 06 13

United States: +1 (1) 631 570 56 13

Link to webcast
https://creo-live.creomediamanager.com/a62cd97b-ff6a-4627-9cec-575b30bce201

For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
 
USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.
 
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.

Attachments
INVITATION TO IMMUNOVIA’S Q3 PRESENTATION

Datum 2025-11-20, kl 13:00
Källa MFN
Bifogade filer
INVITATION TO IMMUNOVIA’S Q3 PRESENTATION